Patients treated with Immune checkpoint inhibitors like antiCTLA4, antiPD1 and antiPDL1 drugs, may develop immunerelated adverse events. As any tissue can be involved, it is very important to recognize these side effects early and manage them promptly and effectively to get the best outcome for the patients.
In this educational video of the 'How To' series, John Haanen explains how to manage immunotherapy induced colitis, hepatitis and pneumonitis.

Download the full ESMO Guidelines Slides Set:
https://www.esmo.org/Guidelines/ESMO...

Produced by the European Society for Medical Oncology
http://www.esmo.org